Clinical Trial Update: Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS) [Phase 3]

View source ↗

Summary

Phase 3 trial of ALXN1210 in treatment-naïve adults and adolescents with atypical hemolytic uremic syndrome has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome

Drugs mentioned

• ALXN1210 (ALXN1210)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Atypical Hemolytic Uremic Syndrome (aHUS) | Phase 3 | Status: COMPLETED | Results posted: 2020-02-10